Cargando…

A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor

Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Yuan, Zhang, Da-Wei, Wen, Juan, Cao, Qing, Chen, Ren-Jie, Zhu, Jin, Feng, Zhen-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292017/
https://www.ncbi.nlm.nih.gov/pubmed/22408448
http://dx.doi.org/10.3390/ijms13022208
_version_ 1782225218209579008
author Mao, Yuan
Zhang, Da-Wei
Wen, Juan
Cao, Qing
Chen, Ren-Jie
Zhu, Jin
Feng, Zhen-Qing
author_facet Mao, Yuan
Zhang, Da-Wei
Wen, Juan
Cao, Qing
Chen, Ren-Jie
Zhu, Jin
Feng, Zhen-Qing
author_sort Mao, Yuan
collection PubMed
description Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC (2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) + Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P < 0.01). Immunohistochemical staining showed that VEGF expression in NPC xenografts was significantly inhibited in the combination group compared to the Fab (4 mg/kg) group (P < 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth in vivo and combination therapy showed apparent synergistic anti-tumor effects, which may be due to the induction of tumor cell apoptosis and the downregulation of VEGF expression. These results suggest that the novel combined therapy utilizing traditional chemotherapeutics and antibody-targeted therapy could be a promising strategy for the treatment of NPC.
format Online
Article
Text
id pubmed-3292017
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-32920172012-03-09 A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor Mao, Yuan Zhang, Da-Wei Wen, Juan Cao, Qing Chen, Ren-Jie Zhu, Jin Feng, Zhen-Qing Int J Mol Sci Article Combined therapy emerges as an attractive strategy for cancer treatment. The aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC (2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) + Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P < 0.01). Immunohistochemical staining showed that VEGF expression in NPC xenografts was significantly inhibited in the combination group compared to the Fab (4 mg/kg) group (P < 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth in vivo and combination therapy showed apparent synergistic anti-tumor effects, which may be due to the induction of tumor cell apoptosis and the downregulation of VEGF expression. These results suggest that the novel combined therapy utilizing traditional chemotherapeutics and antibody-targeted therapy could be a promising strategy for the treatment of NPC. Molecular Diversity Preservation International (MDPI) 2012-02-17 /pmc/articles/PMC3292017/ /pubmed/22408448 http://dx.doi.org/10.3390/ijms13022208 Text en © 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Mao, Yuan
Zhang, Da-Wei
Wen, Juan
Cao, Qing
Chen, Ren-Jie
Zhu, Jin
Feng, Zhen-Qing
A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor
title A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor
title_full A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor
title_fullStr A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor
title_full_unstemmed A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor
title_short A Novel LMP1 Antibody Synergizes with Mitomycin C to Inhibit Nasopharyngeal Carcinoma Growth in Vivo Through Inducing Apoptosis and Downregulating Vascular Endothelial Growth Factor
title_sort novel lmp1 antibody synergizes with mitomycin c to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292017/
https://www.ncbi.nlm.nih.gov/pubmed/22408448
http://dx.doi.org/10.3390/ijms13022208
work_keys_str_mv AT maoyuan anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT zhangdawei anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT wenjuan anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT caoqing anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT chenrenjie anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT zhujin anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT fengzhenqing anovellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT maoyuan novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT zhangdawei novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT wenjuan novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT caoqing novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT chenrenjie novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT zhujin novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor
AT fengzhenqing novellmp1antibodysynergizeswithmitomycinctoinhibitnasopharyngealcarcinomagrowthinvivothroughinducingapoptosisanddownregulatingvascularendothelialgrowthfactor